Iovance Biotherapeutics Inc. Stock
Heavy losses for Iovance Biotherapeutics Inc. today as the stock fell by -€0.560 (-4.310%).
Currently there is a rather positive sentiment for Iovance Biotherapeutics Inc. with 19 Buy predictions and 3 Sell predictions.
With a target price of 25 € there is potential for a 100.56% increase which would mean more than doubling the current price of 12.47 € for Iovance Biotherapeutics Inc..
So far the community has only identified positive things for Iovance Biotherapeutics Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Iovance Biotherapeutics Inc. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Iovance Biotherapeutics Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Iovance Biotherapeutics Inc. | -4.310% | 12.908% | 3.573% | 93.857% | 59.644% | -46.822% | - |
Ironwood Pharmaceuticals | 0.680% | 2.759% | 2.055% | -22.798% | -26.961% | -18.132% | - |
Sage Therapeutics Inc. | 0.040% | -11.648% | -24.641% | -75.363% | -42.350% | -80.719% | - |
Novocure Ltd | 3.290% | 30.065% | 14.280% | -76.332% | 4.553% | -90.566% | - |
Comments
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Show more
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $19.00 to $21.00. They now have a "buy" rating on the stock.
Show more
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target raised by analysts at Barclays PLC from $18.00 to $22.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for IOVA provided by MarketBeat